Abstract
Objective To observe the effect of antisense oligodeoxynucleotide (AODN) of basic fibroblast growth factor (bFGF) on the rat models of pulmonary fibrosis.Methods Thirty rats were divided into five groups (6 rats of each group):control group,pulmonary fibrosis group,empty vector transfection group,AODN group and RODN group.Lung coefficient was counted,pathologic changes in the lung tissue were observated to determine degree of pulmonary fibrosis,enzyme linked immunosorbent assay (ELISA) was used to determine the concentrations of hydroxyproline in lung tissue homogenate and the expression of bFGF in the serum and bronchoalveolar lavage fluid,and reverse transcription-polymerase chain reaction (RT-PCR) was employed to detect the mRNA expression of bFGF,α-smooth muscle actin (α-SMA),type Ⅰ collagen,transforming growth factor-β1 (TGF-β1),connective tissue growth factor (CTGF),Smad3 and Smad7 in lung tissue homogenate.Results In control group,pulmonary fibrosis gToup,empty vector transfection group,AODN group and RODN group,the lung coefficient was 7.5 ± 1.5,10.8 ± 1.4,11.0 ± 1.4,8.8 ± 1.7 and 12.5 ± 1.6 respectively,the degree of pulmonary fibrosis was 0,2.38 ± 0.52,2.41 ± 0.48,1.62 ± 0.45 and 2.82 ±0.54 respectively,the synthesis of bFGF was significantly decreased in AODN group and significantly increased in RODN group (P ＜ 0.05),the concentration of HYP was markedly decreased in AODN group and markedly increased in RODN group (P ＜ 0.05),the mRNA expression of bFGF,α-SMA,type Ⅰ collagen,TGF-β1,CTGF and Smad3 was markedly decreased in AODN group and markedly increased RODN group (P ＜ 0.05),and that of Smad7 was markedly increased in AODN group and markedly decreased in RODN group.Conclusion:These results demonstrate that AODN of bFGF can inhibit the development of pulmonary fibrosis induced by Bleomycyn in rats possibly by down-regulating the TGF-β1-Smad signaling pathway. Key words: Basic fibroblast growth factor; Antisense oligodeoxynucleotide; Pulmonary fibrosis; Transforming growth factor-β1-Smad
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
